The purpose of this study is to test the safety of a drug called M3814 (peposertib) in combination with a specific type of radiation therapy (hypofractionated radiation) in patients with locally advanced pancreatic cancer. This study will test different doses of M3814 to see which dose is safer for people when combined with hypofractionated radiation.

This study is for people who have stage III colon cancer that has been treated with surgery but has spread to some of the lymph nodes, or who have stage II or stage III colon cancer that has been treated with surgery and has a higher risk of returning based on positive circulating tumor DNA (ctDNA) results. ctDNA is DNA that has been released from tumor cells into the bloodstream. This DNA can be measured using a blood test.
   

This study is open to men and women over the age of 18 who have Kaposi Sarcoma (KS). Kaposi Sarcoma is a cancer related to a viral infection, known as the Kaposi sarcoma-associated herpesvirus, or KSHV.

This study aims to learn more about whether the experimental medication osimertinib (TAGRISSO) is more effective than placebo in participants with Epidermal Growth Factor Receptor (EGFR) mutated stage IA2 or IA3 non small cell lung cancer (NSCLC) after complete surgical removal of the tumor. 

The purpose of this study is to evaluate the study drug, DS-8201a (also known as Enhertu or fam-trastuzumab deruxtecan-nxki) for advanced solid tumors. The study aims to see how DS-8201a affects the levels of certain proteins and immune cells in solid tumors, how well it works against cancer cells, and how safe and tolerable it is.

The United States Food and Drug Administration (FDA) has approved DS-8201a for the treatment of patients with advanced HER2-positive breast or gastric cancer.

This study is being done to determine if the study drug, Olaparib has an effect on urothelial carcinoma or other non-prostate genitourinary cancers in people with DNA-repair changes in their genes.

This study aims to determine if Olaparib is better or worse than the usual approach for urothelial cancer or other non-prostate genitourinary cancers. There is no standard of care for these cancers, but people who are not participating in a study are usually treated with single-drug taxane chemotherapies (e.g. paclitaxel, abraxane, docetaxel).

This is an observational study that will collect data from oncology patients diagnosed with COVID-19 including their demographics, diagnosis, stage of treatment, symptom presentation, severity of disease, COVID-19 directed treatment and impact on cancer care.

The purpose is to describe and disseminate, in real time, the evolving clinical course of children, adolescents, and young adults diagnosed with cancer and infected with SARS-COV-2 and/or who have received a COVID-19 vaccine via a national database registry.

The purpose of this study is to examine the effects of an abstinence period on semen parameters and sperm quality. There is no current data regarding the best time for men to produce a semen sample that will produce the highest quality sperm. This study aims to determine whether shorter abstinence periods may result in improved sperm quality.

Participants will be required to provide a total of 6 semen samples. The semen samples will be requested to be produced after 7 days, 5 days, 2 days, 1 day, and 3 hours of abstinence from sexual activity.

As the number of available treatments for psoriasis and atopic dermatitis grow, there is a need to find a way to identify which treatment will work best for each person. The goal of this study is to develop a test called a gene expression assay to see if the assay can predict treatment success and/or failure in participants with atopic dermatitis or psoriasis. 

This study aims to assess a mobile iPhone app called MAYA for use in middle-aged and older adults with anxiety or mood disorders.

Participants will be asked to use the app for at least two days a week, 20 minutes each day, for six weeks. Participants will have weekly check-ins as well as longer assessments at the beginning of the study, week 3, week 6 (end of treatment), and week 12 (follow up).